The pharmaceutical industry is actively exploring low global warming (GWP) propellants as alternatives to the currently used propellants for pressurised metered-dose inhalers to reduce the devices carbon footprint.
The selection of a low GWP propellant in a metered-dose inhaler is a substantial change to the product that will require a good deal of consideration with regards to the formulation and container closure system that is used.
The webinar will give an overview of the current environmental challenges within the pMDI industry and and the impact low GWP propellants and container closure systems will be presented. Viewers will also get an understanding of the current regulatory landscape and the expectations of the regulatory authorities (FDA) for low GWP propellant pMDIs will be presented.
The webinar will explore the current low GWP propellant pMDI formulation developments ongoing within the industry. Container closure systems (CCS) will also need to be reviewed when developing a low GWP propellant pMDI, as the new propellants have different physico-chemical properties. pMDI Canister, valve and actuator geometries would be needed to be optimised along with formulation development to achieve bioequivalence with existing pMDI products.
The webinar will discuss potential obstacles when developing a low GWP propellant pMDI and explore strategies needed to accelerate the product development and selection of CCS.
The webinar will end with a Q&A session
Key Learning Objectives:
- Overview of the current environmental challenges and the impact low GWP propellants will have on the Container Closure System (CCS)
- Understand the ongoing formulation developments within the market
- Understand how to accelerate development programmes and container closure systems
- Current expectations from the regulatory authorities on low GWP Propellant MDIs
Register